A Comparison of Recombinant Rabbit Monoclonal Clones Against PD-L1

Access to a diverse range of anti-PD-L1 recombinant monoclonal antibodies ensures researchers have the best chance of pinpointing the optimal PD-L1 clone for a research project or diagnostic assay. Abcam has just expanded its range of these antibodies, with three of them used in FDA-approved companion diagnostic assays (28-8, 73-10, and SP142 clones).

Several independent studies have compared these PD-L1 clones alongside the CAL10 clone. The table below shows a selection of data that allows users to decide which clone is the best option for their specific needs.

Product name Clone 28-8 Clone 73-10 Clone SP142 Clone EPR20529 Clone CAL10
Antibody type Recombinant Recombinant Recombinant Recombinant Recombinant
Epitope Extracellular Intracellular Intracellular Extracellular Intracellular
Host/Clonality Rabbit monoclonal Rabbit monoclonal Rabbit monoclonal Rabbit monoclonal Rabbit monoclonal
Species reactivity Human Human Human Mouse Human
Applications verified IHC-P, ICC/IF, Flow cytometry, WB IHC-P, WB, ICC/IF, WB, Flow cytometry, ELISA IHC-P, ICC/IF, IP, WB ICC/IF, IP, WB IHC-P
Ideal usage IHC autostainer IHC autostainer ICC human ICC mouse IHC autostainer

PD-L1 Background

PD-L1, also known as B7-H1 and CD274, is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to avoid anti-tumor responses.

PD-L1 plays a critical role in inhibiting the activation and proliferation of T cells and has recently been found to be a vital target in the treatment of cancer. Additionally, detection of the PD-L1 protein via immunohistochemistry (IHC) serves as a predictive biomarker assay within anti-PD-1 or PD-L1 therapies.

Due to these important uses and applications, it is essential that researchers have reliable, reproducible tools in place to detect and measure PD-L1.

Independent PD-L1 Testing

There are independent comparisons available for PD-L1 clones conducted using IHC – in particular, the Blueprint phase 2 project. The Blueprint project is a joint initiative being undertaken by industry and academia to explore the viability of harmonizing the use of various PD-L1 clones within a clinical setting.

Within these comparisons, the authors conclude that their "results showed highly comparable staining by 22C3, 28-8 and SP263 assays, less sensitivity with SP142 assay, and higher sensitivity with 73-10 assay (ab228415) to detect PD-L1 expression on TC (tumor cells).”

The image below illustrates a representative sample of PD-L1 staining from the Blueprint project, specifically looking at the five assays used in the project itself.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) of lung cancer tissue samples comparing the staining of anti-PD-L1 with different monoclonal antibodies. ab228415 (73-10) showed higher sensitivity to PD-L1 compared with the other clones.

Figure 1. Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) of lung cancer tissue samples comparing the staining of anti-PD-L1 with different monoclonal antibodies. ab228415 (73-10) showed higher sensitivity to PD-L1 compared with the other clones.

About Abcam

Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.

Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Oct 31, 2018 at 9:30 AM

Other White Papers by this Supplier